Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.51 |
| ▸ | GSK3A | P49840 | 16/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 12/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 12/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262734 | 0.73 | GSK3B (0.50) | GSK3BGSK3ACDK5CDK5R1CCNB2 | |
| SCHEMBL29124061 | 0.73 | CDK5 (0.47) | GSK3BGSK3ACDK5CDK5R1CCNB2 | |
| SCHEMBL18289479 | 0.72 | AHR (0.50) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL5865477 | 0.71 | MAPT (0.52) | MAPTKDM4EMEN1LMNAHSP90AA1 | |
| SCHEMBL7658852 | 0.69 | KDM4E (0.48) | MAPTKDM4EMEN1LMNAHSP90AA1 | |
| SCHEMBL3335156 | 0.69 | MAPT (0.48) | MAPTKDM4EMEN1LMNAHSP90AA1 | |
| SCHEMBL2070779 | 0.69 | NEK2 (0.36) | GSK3BGSK3ACDK5CDK5R1CCNB2 | |
| SCHEMBL2255938 | 0.69 | KDM4E (0.48) | MAPTKDM4EMEN1LMNAHSP90AA1 | |
| SCHEMBL18403203 | 0.69 | PNMT (0.43) | GSK3BGSK3ACDK5CDK5R1CCNB2 | |
| SCHEMBL13859959 | 0.68 | MAPT (0.71) | MAPTKDM4EMEN1LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313732-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-05-28 | — | — | EP | claimed |
| WO-2002020524-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | claimed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | claimed |
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| EP-1313732-B1 | OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| US-6720332-B2 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20030195189-A1 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2002020524-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020524-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | GSK3B 228/4885GSK3A 205/4885CDK5 122/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | GSK3B 256/4885GSK3A 180/4885CDK5 250/4885 |
| US-20030195189-A1 | Oxindole derivatives | CDK4, CCNI, CCNO | GSK3B 1097/4885GSK3A 1261/4885CDK5 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.